How often do vascepa side effects occur?

How common are Vascepa side effects in clinical use?
In placebo-controlled trials, muscle and joint pain occurred in roughly 4-7% of patients taking icosapent ethyl. Peripheral edema was reported in about 2-3%. Atrial fibrillation requiring hospitalization appeared in 3% of Vascepa users versus 2% on placebo. Bleeding events were slightly higher than placebo but remained below 12% overall.

What bleeding risk do patients actually face?
Serious bleeding was observed in 2.7% of patients on Vascepa compared with 2.1% on placebo. Most events were mild to moderate and did not require drug discontinuation. Concomitant use with anticoagulants or antiplatelet agents can increase this risk, which is why prescribing information advises monitoring.

Does Vascepa cause liver enzyme changes?
Elevations in liver enzymes (ALT/AST) above three times the upper limit of normal were seen in 1.5% of treated patients. Routine liver-function monitoring is not mandated, but clinicians often check baseline values in patients with known hepatic impairment.

How do side effects differ at the 2-gram versus 4-gram dose?
The 4-gram daily dose used in cardiovascular-outcome trials produced higher rates of atrial fibrillation and bleeding than the 2-gram dose studied for triglyceride reduction. Discontinuation due to adverse events reached 7% at 4 grams versus 4% at 2 grams.

What happens if side effects appear early?
Most gastrointestinal complaints and muscle aches surface within the first three months. When mild, they often resolve with continued use or temporary dose reduction. Persistent or severe symptoms warrant discontinuation and clinical evaluation.

Are there long-term safety signals beyond the trials?
Post-marketing reports list arthralgia, rash, and taste perversion as the most frequent spontaneous reports. No new major safety issues have emerged since approval. Ongoing surveillance through the FDA Adverse Event Reporting System continues to track rare events such as pancreatitis or severe hypersensitivity.

Which patients report the highest discontinuation rates?
Older adults and those on multiple antithrombotic medications show higher dropout rates in real-world data. Cost and pill burden also contribute to stopping therapy, independent of side-effect severity.